Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1472-6483(10)62069-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of Fertility Outcomes Following Combined Clomiphene and Letrozole Versus Letrozole Therapy for the Treatment of Polycystic Ovarian Syndrome Subfertility.
Cureus
May 2023
Obstetrics and Gynecology, Employee State Insurance Corporation (ESIC) Medical College and Hospital, Faridabad, IND.
Background: Poly Cystic Ovarian Syndrome (PCOS) affects 8-13%of women in their reproductive age and is one of the foremost causes of female subfertility. Traditionally, clomiphene citrate has been the first-line treatment for ovulation induction in PCOS. However, the European Society of Human Reproduction and Embryology (ESHRE) international evidence-based guidelines in 2018 recommended the use of letrozole as first-line therapy for ovulation induction in anovulatory PCOS women, due to better pregnancy and live birth rates.
View Article and Find Full Text PDFThe positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options.
Support Care Cancer
June 2017
Adolescent and Young Adult Program, Princess Margaret Cancer Centre, Toronto, Canada.
Purpose: Minimal data exist regarding documentation of therapy-associated infertility risk (IR) and fertility preservation (FP) options during the initial oncology consultation prior to systemic therapy. This study investigated factors affecting IR/FP documentation and assessed the effect of implementation of an Adolescent and Young Adult (AYA) program on documentation rates.
Methods: A retrospective review of charts of patients receiving gonadotoxic therapy was undertaken for documentation of IR/FP pre- and post-implementation of an AYA program.
Bortezomib treatment causes long-term testicular dysfunction in young male mice.
Mol Cancer
June 2014
Department of Women's and Children's Health, Astrid Lindgren Children's Hospital, Pediatric Endocrinology Unit Q2:08, Karolinska Institutet & University Hospital, SE-171 76 Stockholm, Sweden.
Background: With increased long-term survivors of childhood cancer patients, therapy-associated infertility has become one of the most common late side-effects and significantly affects their life-quality. Therefore, evaluation of anti-cancer agents on male reproduction and infertility prevention are urgently demanding. The proteasome inhibitor bortezomib has been launched in clinical trials for childhood cancers, however, its potential side effects on reproduction have so far been neither investigated experimentally nor reported in treated children.
View Article and Find Full Text PDFRole of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.
Am J Hematol
October 2012
Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. The current treatment protocol for ALL involves an intense chemotherapy regimen yielding cure rates of nearly 80%. However, new therapies need to be designed not only to increase the survival rate but also to combat the risk of severe therapy associated toxicities including secondary malignancies, growth problems, organ damage, and infertility.
View Article and Find Full Text PDFPurpose: Pre-menopausal women with cancer are at risk of therapy-associated infertility, premature menopause, and sexual dysfunction. However, it is unknown whether oncologists adequately address these risks during treatment planning. We conducted a study to evaluate physician-patient discussions addressing the impact of cancer treatment and actual treatment effects on fertility, menopause status, and general sexual health.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!